Project: Research project

Project Details


This vaccine program is comprised of a group of interactive investigators
with a long standing commitment to the AIDS vaccine research agenda.
Our V3 loop and gp41 peptides conjugated to PPD and to M. tuberculosis
(TB) derived protein carriers have induced among other neutralizing
antibodies to primary isolates in humans and in animals. New conserved
glycoproteins in the V1/V2 regions appear also to induce broad
The overall goal of this program is to exploit our experience to develop:
1) improved preventative peptide AIDS vaccines to include but not limited
to the V3 loop and gp41 cocktails. The flexibility of our peptide vaccine
development will allow us to rapidly and inexpensively incorporate new
epitopes such as those related to HIV-1 co-receptors.
2) Dr. Pinter will add a new dimension to this program by conjugating to
PPD highly conserved epitopes of the V1/V2 domain of gp120 which mediate
potent neutralization of M tropic primary HIV isolates.
3) Dr. Goldstein's human CD4/CCR5 transgenic mouse will serve as an in
vivo model for all vaccine constructs. In addition the HIV infected SCID-
hu mice (core) will provide an in vivo system to test the biological
function of neutralizing antibodies generated in animals and in humans.

This collaborative project focuses on preventative vaccines but will
utilize also therapeutic vaccination as a model for preventative vaccines.
In limited clinical trials out PPD V3 pentapeptide conjugate vaccine
induced in HIV+PPD+ subjects high titers of primary isolate neutralizing
antibodies and reduced plasma viral loads. In collaboration with Dr. Ali
Javadian, we will evaluate the potential of a polyepitopic V3, gp41
peptide-PPD-conjugate vaccine to induce neutralizing antibodies and to
reduce viral loads in BCG immunized HIV+ chimps.

This consortium will continue to collaborate with its commercial partners,
ThereGuide and the Swiss Serum and Vaccine Institute (SSVI) to prepare GLP
vaccine available for clinical trials. Clinical trials will initially
continue abroad (Israel; Brazil) where a large PPD+ cohort is readily
available. Future studies in the US will be designed with NIAID program
Effective start/end date5/15/986/30/99


  • Drug Discovery
  • Microbiology (medical)
  • Infectious Diseases
  • Molecular Medicine
  • Biochemistry
  • Biotechnology
  • Virology
  • Immunology